In vitro experimental study of MC-PMMA containing vancomycin for the prevention of infection in open bone defects.

In this study, vancomycin, bone cement (PMMA) and mineralized collagen (MC) were mixed in order to obtain a new composite drug-carrying biomaterial, which has good results in both drug slow release, good biocompatibility, and good growth of osteoblasts, osteoclasts, and mesenchymal stem cells on the surface of the biomaterial, which provides a new therapeutic idea for the clinical treatment of bone defect infections. In this study, the drug retardation system of vancomycin and mineralized collagen composite bone cement-carrying biomaterials was prepared in proportion to the drug retardation system, and the experimental studies were carried out using electron microscope scanning, HPLC drug retardation analysis, in vitro antimicrobials, and co-cultivation of osteoclasts, osteoblasts, and mesenchymal stem cells. We found that the composite drug-carrying material of vancomycin, bone cement and mineralized collagen had good slow-release effect and antimicrobial properties, and the addition of vancomycin and bone cement to mineralized collagen material had even better drug-release efficiency than that of bone cement plus vancomycin alone. In vitro antimicrobial showed that the composite material has excellent antimicrobial effect against Staphylococcus aureus. Co-culture of osteoblasts, osteoclasts and mesenchymal stem cells with the material showed that the cells were morphologically complete on the surface of the composites with good growth status. Vancomycin, bone cement and mineralized collagen composite drug-carrying biomaterials have excellent slow-release effect and antimicrobial properties with good biocompatibility, which is a new therapeutic idea for the future clinical treatment of bone defect infections.